Telephone: 910-200-5156; FAX: 910-458-2040
Article first published online: 24 AUG 2006
Copyright © 2006 American Association for the Study of Liver Diseases
Volume 12, Issue 9, pages 1381–1389, September 2006
How to Cite
Schiano, T. D., Charlton, M., Younossi, Z., Galun, E., Pruett, T., Tur-Kaspa, R., Eren, R., Dagan, S., Graham, N., Williams, P. V. and Andrews, J. (2006), Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study. Liver Transpl, 12: 1381–1389. doi: 10.1002/lt.20876
See Editorial on Page 1317
N.G., S.D., R.E., and J.A. are (or were at the time the work described was conducted) employees of XTL Biopharmaceuticals Inc. Otherwise, the investigators who conducted the study described herein received compensation for their involvement but have no proprietary or stock interest in XTL Biopharmaceuticals Ltd., other than that which might have been acquired through public transactions.
- Issue published online: 24 AUG 2006
- Article first published online: 24 AUG 2006
- Manuscript Accepted: 22 MAY 2006
- Manuscript Received: 10 JAN 2006
- XTL Biopharmaceuticals Ltd.
A randomized, double-blind, dose-escalation study evaluated the safety and efficacy of hepatitis C virus (HCV)-AbXTL68, a neutralizing, high-affinity, fully human, anti-E2 monoclonal antibody, in 24 HCV-positive patients undergoing liver transplantation. HCV-AbXTL68 or placebo was administered at doses from 20-240 mg as 2-4 infusions during the first 24 hours after transplantation, followed by daily infusions for 6 days, weekly infusions for 3 weeks, and either 2 or 4 weekly infusions for 8 weeks. Serum concentrations of total anti-E2 obtained during daily infusions of 120-240 mg HCV-AbXTL68 were 50-200 μg/mL above concentrations in the placebo group. Median serum concentration of HCV RNA dropped below baseline in all groups immediately after transplantation. On day 2, median change from baseline in HCV RNA was −1.8 and −2.4 log in the 120-mg and 240-mg groups, respectively, compared with −1.5 log with placebo. The difference was lost after day 7 when the dosing frequency was reduced. The coincidence of increases in anti-E2 with decreases in HCV RNA concentration indicate that the dose-related changes in HCV RNA concentration were a result of HCV-AbXTL68 administration in the 120- and 240-mg groups. The overall incidence of nonfatal serious adverse events was higher with placebo (60%) vs. all active treatments combined (42%). In conclusion, HCV-AbXTL68 may decrease serum concentrations of HCV RNA in patients after liver transplantation. Studies evaluating more frequent daily dosing at doses >120 mg are necessary to investigate sustained viral suppression in this population. Liver Transpl 12:1381–1389. 2006. © 2006 AASLD.